• 1
    Höger PH. Topische Antibiotika und Antiseptika. Hautarzt 1998;49:331347.DOI: 10.1007/s001050050754
  • 2
    Le Coz C-J, Santinelli F. Facial contact dermatitis from chloramphenicol with cross-sensitivity to thiamphenicol. Contact Dermatitis 1998;38:108109.
  • 3
    Wereide K. Sensitivity to azidamphenicol. Contact Dermatitis 1975;1:271272.
  • 4
    Vincenzi C, Morelli R, Bardazzio F, Guerra L. Contact dermatitis from chloramphenicol in a leg ulcer cream. Contact Dermatitis 1991;1:271273.
  • 5
    Lafarge-Frayssinet C, Robbana-Barnat S, Frayssinet C, Toucas L, Decloitre F. Cytotoxicity and DNA damaging potency of chloramphenicol and six metabolites: a new evaluation in human lymphocytes and Raji cells. Mutat Res 1994;320:207215.
  • 6
    Nyfeler B, Pichler WJ. The lymphocyte transformation test for the diagnosis of drug allergy: sensitivity and specificity. Clin Exp Allergy 1997;27:175181.
  • 7
    Rönnau AC, Sachs B, Schmiedeberg SV, Ruzicka T, Gleichmann E, Schuppe H-C. Cutaneous adverse reaction to ciprofloxacin: diagnosis by specific lymphocyte proliferation in vitro. Acta Derm Venereol 1997;77:285288.
  • 8
    Wilkinson DS, Fregert S, Magnusson B, et al. Terminology of contact dermatitis. Acta Derm Venereol 1970;50:287292.
  • 9
    Yunis AA, Arimura GK, Isildar M. DNA damage induced by chloramphenicol and its nitroso derivative: damage in intact cells. Am J Hematol 1987;24:7784.
  • 10
    Griem P, Wulferink M, Sachs B, Gonzales JB, Gleichmann E. Allergic and autoimmune reactions to xenobiotics: how do they start? Immunol Today 1998;19:133141.
  • 11
    Uetrecht JP. The role of leucocyte generated reactive metabolites in the pathogenesis of idiosyncratic drug reactions. Drug Metabol Rev 1992;24:299366.
  • 12
    Pichler WJ, Zanni M, Von Greyerz S, Schnyder B, Mauri-Hellweg D, Wendland T. High IL-5 production by human drug-specific T cell clones. Int Arch Allergy Immunol 1997;113:177180.
  • 13
    Brugnolo F, Annunziato F, Sampognaro S, et al. Highly Th2-skewed cytokine profile of beta-lactam specific T cells from nonatopic subjects with adverse drug reactions. J Immunol 1999;163:10531059.